Broward Health Deal And New Coverage Could Be A Game Changer For Oscar Health (OSCR)

• Oscar Health recently gained fresh analyst coverage from Stephens & Co., which highlighted its technology-focused approach to Affordable Care Act exchanges, while the company also secured an agreement that will add Broward Health’s providers and facilities to its South Florida network starting in 2026.
• This combination of greater Wall Street attention and a broader provider network could influence how investors assess Oscar’s growth potential and competitive positioning in the ACA marketplace.
• We’ll now examine how Broward Health’s planned addition to Oscar’s South Florida network could influence the company’s existing investment narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Oscar Health Investment Narrative Recap

To own Oscar Health, you need to believe its tech-enabled ACA exchange model can move from high growth to sustainable profitability, while managing policy and pricing uncertainty. The Stephens & Co. coverage and Broward Health network expansion may support investor confidence in Oscar’s growth story, but they do not materially change the near term focus on margin recovery and the policy risk around expiring ACA premium subsidies heading into 2026.

Among recent developments, the planned 2026 expansion of Oscar’s South Florida footprint, including access to Broward Health, sits alongside a wider push into new ACA markets such as Southern and Central Florida, Ohio, and parts of the Southeast. For investors watching catalysts, these rollouts tie directly into the company’s efforts to grow membership and improve operating leverage, while testing whether its technology and product innovations like Oswell and HelloMeno can support better economics at scale.

But while expansion can help the top line, investors should also be aware that...

Read the full narrative on Oscar Health (it's free!)

Oscar Health’s narrative projects $12.4 billion revenue and $245.4 million earnings by 2028. This requires 4.9% yearly revenue growth and an earnings increase of about $406.6 million from -$161.2 million today.

Uncover how Oscar Health's forecasts yield a $14.38 fair value, a 11% downside to its current price.

Exploring Other Perspectives

Twenty four Simply Wall St Community members place Oscar Health’s fair value between US$11.52 and US$66, reflecting very different return expectations. You can weigh those views against the current focus on margin recovery and policy risk that may shape how the business performs from here.

Explore 24 other fair value estimates on Oscar Health - why the stock might be worth over 4x more than the current price!

Build Your Own Oscar Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Oscar Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com